Start Submission Become a Reviewer

Reading: Biologics: a new weapon in the war against autoimmune joint disease


A- A+
Alt. Display


Biologics: a new weapon in the war against autoimmune joint disease


Harindu Wijesinghe ,

Consultant Rhematologist, Rheumatology Unit, Sri Jayewardenepura General Hospital, LK
X close

Suranjith L Seneviratne,

Consultant Immunologist, Department of Clinical Immunology, St Mary’s Hospital and Imperial College, London, GB
X close

Priyadarshani Galappatthy,

Senior Lecturer, Department of Pharmacology, University of Colombo, LK
X close

Lalith Wijayaratne

Consultant Rheumatologist, Rheumatology Unit, National Hospital of Sri Lanka, LK
X close


Autoimmune joint diseases occur due to uncontrolled abnormal immune responses (autoimmunity). The commonest autoimmune diseases seen in clinical practice are rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and un-differentiated arthritis. These are a source of significant morbidity and some mortality within the population. Non-biologic disease modifying anti-rheumatic drugs (Nonbiologic DMARD’s) commonly used in the treatment of these disorders include: methotrexate, sulpha-salazine, leflunomide, hydroxychloroquine and gold. However, a significant proportion of patients do not show adequate responses to these agents. The last few years has seen the introduction of a class of drugs directed at specific patho-physiological abnormalities identified in these diseases. These drugs have not only brought the promise of better response rates but also the possibility of a cure for some patients. These agents are called biologic disease modifying anti-rheumatic drugs (biologic-DMARDS). Biologic-DMARDS show better response rates and appear to be well tolerated by patients. Currently, the biologic- DMARDS are mainly used in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthropathy. The currently approved biologics for autoimmune diseases are: TNF alpha antagonists (Infliximab, Etanercept, Adalimumab, and Golimumab), IL-1 antagonists (Anakinra), anti CD-20 antibodies (Rituximab), IL-6 antagonists (Tocilizumab) and the T-cell inhibitor (Abatacept). Recently, increased rates of infection have been reported and the long-term safety profiles of the biologic-DMARDS are still unknown. Due to these problems coupled with the prohibitive costs, the exact place of these agents within treatment algorithms is still been defined. In many developed countries these agents are now included in the management with provision of specific guidance on when and how to use them. Our review outlines important pharmacological and clinical aspects of these agents in the treatment of autoimmune joint diseases.


Journal of the Ceylon College of Physicians, 2010, 41, 76-82

Keywords: Biologics
How to Cite: Wijesinghe, H., Seneviratne, S.L., Galappatthy, P. and Wijayaratne, L., 2011. Biologics: a new weapon in the war against autoimmune joint disease. Journal of the Ceylon College of Physicians, 41(2), pp.76–82. DOI:
Published on 02 Nov 2011.
Peer Reviewed


  • PDF (EN)

    comments powered by Disqus